keyword
https://read.qxmd.com/read/38761776/senolytic-combination-of-dasatinib-and-quercetin-attenuates-renal-damage-in-diabetic-kidney-disease
#1
JOURNAL ARTICLE
Xiuli Guo, Si Wen, Jiao Wang, Xiaobian Zeng, Hongyuan Yu, Ying Chen, Xinwang Zhu, Li Xu
BACKGROUND: Senolytic combination of dasatinib and quercetin (DQ) is the most studied senolytics drugs used to treat various age-related diseases. However, its protective activity against diabetic kidney disease (DKD) and underlying mechanisms are uncertain. PURPOSE: To investigate the functions and potential mechanisms of the senolytics DQ on DKD. METHODS: Diabetic db/db mice were administrated DQ or transfected with over-expressed PPARα or shPPARα vector...
May 3, 2024: Phytomedicine
https://read.qxmd.com/read/38761167/novel-therapeutics-to-treat-chronic-pancreatitis-targeting-pancreatic-stellate-cells-and-macrophages
#2
REVIEW
Srikanth Iyer, Macie Enman, Preeti Sahay, Vikas Dudeja
INTRODUCTION: Chronic pancreatitis (CP) is a persistent, recurrent, and progressive disorder that is characterized by chronic inflammation and irreversible fibrosis of the pancreas. It is associated with severe morbidity, resulting in intense abdominal pain, diabetes, exocrine and endocrine dysfunction, and an increased risk of pancreatic cancer. The etiological factors are diverse and the major risk factors include smoking, chronic alcoholism, as well as other environmental and genetic factors...
May 18, 2024: Expert Review of Gastroenterology & Hepatology
https://read.qxmd.com/read/38759318/jinlida-granules-alleviates-cardiac-hypertrophy-and-inflammation-in-diabetic-cardiomyopathy-by-regulating-tp53
#3
JOURNAL ARTICLE
Ting Fang, Jingyi Wang, Shengnan Sun, Xiaoqing Deng, Mei Xue, Fei Han, Bei Sun, Liming Chen
BACKGROUND: JinLiDa granules (JLD) is a traditional Chinese medicine (TCM) used to treat type 2 diabetes mellitus with Qi and Yin deficiency. Clinical evidence has shown that JLD can alleviate diabetic cardiomyopathy, but the exact mechanism is not yet clear. PURPOSE: The purpose of this study was to examine the potential role and mechanism of JLD in the treatment of diabetic cardiomyopathy through network pharmacological analysis and basic experiments. METHODS: The targets of JLD associated with diabetic cardiomyopathy were examined by network pharmacology...
May 10, 2024: Phytomedicine
https://read.qxmd.com/read/38758653/real-time-continuous-glucose-monitoring-in-high-risk-people-with-insulin-requiring-type-2-diabetes-a-randomised-controlled-trial
#4
JOURNAL ARTICLE
Claire S Lever, Jonathan A Williman, Alisa Boucsein, Antony Watson, Rachael S Sampson, Oscar T Sergel-Stringer, Celeste Keesing, Lynne Chepulis, Benjamin J Wheeler, Martin I de Bock, Ryan G Paul
AIMS: To investigate the impact of real-time continuous glucose monitoring (rtCGM) on glycaemia in a predominantly indigenous (Māori) population of adults with insulin-requiring type 2 diabetes (T2D) in New Zealand. METHODS: Twelve-week, multicentre randomised controlled trial (RCT) of adults with T2D using ≥0.2 units/kg/day of insulin and elevated glycated haemoglobin (HbA1c) ≥64 mmol/mol (8.0%). Following a 2-week blinded CGM run-in phase, participants were randomised to rtCGM or control (self-monitoring blood glucose [SMBG])...
May 17, 2024: Diabetic Medicine: a Journal of the British Diabetic Association
https://read.qxmd.com/read/38758435/mitochondria-targeted-esculetin-administration-improves-insulin-resistance-and-hyperglycemia-induced-atherosclerosis-in-db-db-mice
#5
JOURNAL ARTICLE
Gajalakshmi Singuru, Sriravali Pulipaka, Altab Shaikh, Shashikanta Sahoo, Aruna Jangam, Rajamannar Thennati, Srigiridhar Kotamraju
The development and progression of hyperglycemia (HG) and HG-associated atherosclerosis are exacerbated by mitochondrial dysfunction due to dysregulated mitochondria-derived ROS generation. We recently synthesized a novel mitochondria-targeted esculetin (Mito-Esc) and tested its dose-response therapeutic efficacy in mitigating HG-induced atherosclerosis in db/db mice. In comparison to simvastatin and pioglitazone, Mito-Esc administration resulted in a considerable reduction in body weights and improved glucose homeostasis, possibly by reducing hepatic gluconeogenesis, as indicated by a reduction in glycogen content, non-esterified free fatty acids (NEFA) levels, and fructose 1,6-bisphosphatase (FBPase) activity...
May 17, 2024: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://read.qxmd.com/read/38757785/traditional-chinese-medicine-improved-diabetic-kidney-disease-through-targeting-gut-microbiota
#6
REVIEW
Xia-Qing Wu, Lei Zhao, Yan-Long Zhao, Xin-Yao He, Liang Zou, Ying-Yong Zhao, Xia Li
CONTEXT: Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. The gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota. OBJECTIVE: This review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation...
December 2024: Pharmaceutical Biology
https://read.qxmd.com/read/38756658/the-risk-of-endocrine-immune-related-adverse-events-induced-by-pd-1-inhibitors-in-cancer-patients-a-systematic-review-and-meta-analysis
#7
Pengfei Zhao, Ting Zhao, Lihong Yu, Wenming Ma, Wenyu Liu, Chenning Zhang
OBJECTIVE: Endocrinopathies are the most common immune-related adverse events (irAEs) observed during therapy with PD-1 inhibitors. In this study, we conducted a comprehensive systematic review and meta-analysis to evaluate the risk of immune-related endocrinopathies in patients treated with PD-1 inhibitors. METHODS: We performed a systematic search in the PubMed, Embase, and Cochrane Library databases to retrieve all randomized controlled trials (RCTs) involving PD-1 inhibitors, spanning from their inception to November 24, 2023...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38756429/glycemic-management-in-insulin-naive-patients-in-the-inpatient-setting
#8
JOURNAL ARTICLE
Michael B Goldstein, Shahidul Islam, Sophie Nicolich-Henkin, Lauren Bellavia, Stanislaw Klek
OBJECTIVE: The ideal inpatient insulin regimen efficiently attains the target blood glucose range, effectively treats hyperglycemia, and minimizes the risk of hypoglycemia. The objective of this study was to compare glycemic targets achieved by using correctional monotherapy (CM) and basal-bolus therapy (BBT) in insulin-naive patients in the inpatient setting to determine optimal blood glucose management for these patients. DESIGN: This was a retrospective observational cohort study of 792 patients with diabetes not on home insulin therapy who were admitted to an academic hospital over a 5...
2024: Diabetes Spectrum: a Publication of the American Diabetes Association
https://read.qxmd.com/read/38754538/a-network-pharmacology-based-method-to-explore-the-therapeutic-effect-of-honokiol-on-diabetes-with-comorbid-depression-in-mice
#9
JOURNAL ARTICLE
Haonan Sun, Yumin Liu, Xuedong Wang, Luan Shu
The effective treatment of diabetes with comorbid depression is a big challenge so far. Honokiol, a bioactive compound from the dietary supplement Magnolia officinalis extract, possesses multiple health benefits. The present study aims to propose a network pharmacology-based method to elucidate potential targets of honokiol in treating diabetes with comorbid depression and related mechanisms. The antidepressant-like efficacy of honokiol was evaluated in high-fat diet (HFD) induced diabetic mice using animal behavior testing, immuno-staining and western blotting assay...
May 14, 2024: European Journal of Pharmacology
https://read.qxmd.com/read/38752510/letter-to-the-editor-early-identification-of-delayed-wound-healing-in-complex-diabetic-foot-ulcers-treated-with-a-dermal-regeneration-template-a-novel-clinical-target-and-its-risk-factors
#10
JOURNAL ARTICLE
Hewen Guan, Yuankuan Jiang, Jingrong Lin
No abstract text is available yet for this article.
May 16, 2024: International Journal of Surgery
https://read.qxmd.com/read/38751373/lncrna-snhg14-silencing-attenuates-the-progression-of-diabetic-nephropathy-via-the-mir-30e-5p-sox4-axis
#11
JOURNAL ARTICLE
YunXia Wang, JiaJia Yang, Chun Wu, Yuqin Guo, Yuan Ding, Xiujuan Zou
BACKGROUND: Diabetic nephropathy (DN) is a diabetic complication. LncRNAs are reported to participate in the pathophysiology of DN. Here, the function and mechanism of lncRNA small nucleolar RNA host gene 14 (SNHG14) in DN were explored. METHODS: Streptozotocin (STZ)-induced DN mouse models and high glucose (HG)-treated human mesangial cells (MCs) were used to detect SNHG14 expression. SNHG14 silencing plasmids were applied to examine the function of SNHG14 on proliferation and fibrosis in HG-treated MCs...
June 2024: Journal of Diabetes
https://read.qxmd.com/read/38751362/once-daily-oral-small-molecule-glucagon-like-peptide-1-receptor-agonist-lotiglipron-pf-07081532-for-type-2-diabetes-and-obesity-two-randomized-placebo-controlled-multiple-ascending-dose-phase-1-studies
#12
JOURNAL ARTICLE
Clare Buckeridge, Nikolaos Tsamandouras, Santos Carvajal-Gonzalez, Lisa S Brown, Martha Hernandez-Illas, Aditi R Saxena
AIM: To investigate the effects of lotiglipron (PF-07081532), a once-daily, oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes (T2D) and/or obesity. MATERIALS AND METHODS: Two Phase 1 randomized, double-blind, placebo-controlled, multiple-ascending-dose studies were conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of lotiglipron. RESULTS: Across the studies, 74 participants with T2D were treated for 28 or 42 days, and 26 participants with obesity without diabetes were treated for 42 days, following randomization to placebo or lotiglipron (target doses 10-180 mg/day, with dose titration to higher target doses)...
May 16, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38751069/rof-2-as-an-aggregation-induced-emission-aie-probe-for-multi-target-amyloid-detection-and-screening-of-amyloid-inhibitors
#13
JOURNAL ARTICLE
Yijing Tang, Dong Zhang, Jie Zheng
Misfolding and aggregation of amyloid peptides into β-structure-rich fibrils represent pivotal pathological features in various neurodegenerative diseases, including Alzheimer's disease (AD), type II diabetes (T2D), and medullary thyroid carcinoma (MTC). The development of effective amyloid detectors and inhibitors for probing and preventing amyloid aggregation is crucial for diagnosing and treating debilitating diseases, yet it poses significant challenges. Here, an aggregation-induced emission (AIE) molecule of ROF2 with multifaceted functionalities as an amyloid probe and a screening tool for amyloid inhibitors using different biophysical, cellular, and worm assays, are reported...
May 15, 2024: Small
https://read.qxmd.com/read/38750902/induction-of-mitochondrial-toxicity-by-non-steroidal-anti-inflammatory-drugs-nsaids-the-ultimate-trade-off-governing-the-therapeutic-merits-and-demerits-of-these-wonder-drugs
#14
REVIEW
Somnath Mazumder, Samik Bindu, Subhashis Debsharma, Uday Bandyopadhyay
Non-steroidal anti-inflammatory drugs (NSAIDs) are most extensively used over-the-counter FDA-approved analgesic medicines for treating inflammation, musculoskeletal pain, arthritis, pyrexia and menstrual cramps. Moreover, aspirin is widely used against cardiovascular complications. Owing to their non-addictive nature, NSAIDs are also commissioned as safer opioid-sparing alternatives in acute trauma and post-surgical treatments. In fact, therapeutic spectrum of NSAIDs is expanding. These "wonder-drugs" are now repurposed against lung diseases, diabetes, neurodegenerative disorders, fungal infections and most notably cancer, due to their efficacy against chemoresistance, radio-resistance and cancer stem cells...
May 13, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38749508/clinical-perspectives-on-the-frequency-of-hypoglycemia-in-treat-to-target-randomized-controlled-trials-comparing-basal-insulin-analogs-in-type-2-diabetes-a-narrative-review
#15
REVIEW
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
The objective of this review was to comprehensively present and summarize trends in reported rates of hypoglycemia with one or two times per day basal insulin analogs in individuals with type 2 diabetes to help address and contextualize the emerging theoretical concern of increased hypoglycemic risk with once-weekly basal insulins.Hypoglycemia data were extracted from treat-to-target randomized clinical trials conducted during 2000-2022. Published articles were identified on PubMed or within the US Food and Drug Administration submission documents...
May 14, 2024: BMJ Open Diabetes Research & Care
https://read.qxmd.com/read/38743496/elevated-apolipoprotein-c3-augments-diabetic-kidney-disease-and-associated-atherosclerosis-in-type-2-diabetes
#16
JOURNAL ARTICLE
Jocelyn Cervantes, Juraj Koska, Farah Kramer, Shreeram Akilesh, Charles E Alpers, Adam E Mullick, Peter Reaven, Jenny E Kanter
Diabetes increases the risk of both cardiovascular disease and kidney disease. Notably, most of the excess cardiovascular risk in people with diabetes is in those with kidney disease. Apolipoprotein C3 (APOC3) is a key regulator of plasma triglycerides, and it has recently been suggested to play a role in both type 1 diabetes-accelerated atherosclerosis and kidney disease progression. To investigate if APOC3 plays a role in kidney disease in people with type 2 diabetes, we analyzed plasma levels of APOC3 from the Veterans Affairs Diabetes Trial (VADT)...
May 14, 2024: JCI Insight
https://read.qxmd.com/read/38742811/mir-4645-3p-attenuates-podocyte-injury-and-mitochondrial-dysfunction-in-diabetic-kidney-disease-by-targeting-cdk5
#17
JOURNAL ARTICLE
Yue Zhang, Shunjie Xia, Xiaoxi Tian, Liming Yuan, Yuan Gao, Dan Liu, Huimin Qi, Shuo Wang, Zanchao Liu, Yang Li, Zhe Zhao, Wei Liu
Podocyte injury plays a critical role in the progression of diabetic kidney disease (DKD), but the underlying cellular and molecular mechanisms remain poorly understanding. MicroRNAs (miRNAs) can disrupt gene expression by inducing translation inhibition and mRNA degradation, and recent evidence has shown that miRNAs may play a key role in many kidney diseases. In this study, we identified miR-4645-3p by global transcriptome expression profiling as one of the major downregulated miRNAs in high glucose-cultured podocytes...
May 31, 2024: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://read.qxmd.com/read/38738549/underuse-of-glp-1-receptor-agonists-in-the-management-of-type-2-diabetes-despite-a-favorable-benefit-safety-profile
#18
REVIEW
André J Scheen
INTRODUCTION: Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a key objective in T2DM. AREAS COVERED: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM in placebo-controlled trials, a finding confirmed in observational studies compared with other glucose-lowering agents...
May 13, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38736272/study-on-the-material-basis-of-zhujing-pill-in-treating-fundus-lesions-through-component-analysis-and-network-pharmacology
#19
JOURNAL ARTICLE
Yijie Liu, Jiali Wang, Xiaoxiang Yu, Jing Hu, Xiuyan Sun
Zhujing pill (ZP) is a famous Chinese herbal formula that has been widely used to treat diabetic retinopathy, macular degeneration, retinitis pigmentosa and other fundus lesions. In this study, the material basis and mechanism of ZP in the treatment of fundus lesions were evaluated via the high-performance liquid chromatography fingerprint, ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry, network pharmacology and molecular docking. A total of 32 common components were found and 31 components were identified in 15 batches of ZP samples...
May 12, 2024: Biomedical Chromatography: BMC
https://read.qxmd.com/read/38736262/mechanism-of-microrna-regulating-apoptosis-after-reperfusion-in-patients-with-mechanical-thrombectomy
#20
JOURNAL ARTICLE
Z J Chen, J Han
Stroke is the second leading cause of death worldwide. Understanding of gene expression dynamics could bring new approaches in diagnostics and therapy of stroke. Small noncoding molecules termed 'microRNA' represent the most flexible network of gene expression regulators. To screen out miRNAs that are mainly regulated during reperfusion in mechanically embolized patients, and study their mechanisms of action in reperfusion injury after thrombectomy, in order to find new therapeutic targets for mechanically embolized patients...
April 2024: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
keyword
keyword
48097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.